Skip to main content

Table 1 Baseline characteristics of the HR+/HER2− patients in two cohorts

From: Real-world data on breast pathologic complete response and disease-free survival after neoadjuvant chemotherapy for hormone receptor-positive, human epidermal growth factor receptor-2-negative breast cancer: a multicenter, retrospective study in China

Variable

Breast pCR (N=57)

Breast non-pCR (N=327)

p value

Age (years)

47.68 ± 9.36

48.87 ± 10.42

 

 < 50 years

32

174

0.714

 ≥50 years

25

153

 

BMI (kg/m2)

23.05 ± 2.98

23.42 ± 2.78

 

 <18.5

3

6

0.037

 18.5~24.9

45

224

 

 ≥25.0

9

97

 

Tumor size (cm)

3.46 ± 1.70

3.44 ± 1.39

0.946

Menstrual status

 Premenopause

40

200

0.195

 Menopause

17

127

 

cT stage

 1

6

19

0.123

 2

44

235

 

 3

7

73

 

cN stage

 0

16

117

0.505

 1

33

173

 

 2

8

37

 

Histological type

 IDC

53

300

0.809

 ILC

3

16

 

 Others

1

11

 

ER status

 <10%

7

16

0.030

 ≥10%

50

311

 

PR status

 <20%

32

121

0.007

 ≥20%

25

205

 

Her2 status (IHC)

 −

13

86

0.150

 +

23

160

 

 ++

21

18

 

Ki67 status

 <15%

6

88

0.010

 ≥15%

48

230

 

Surgical type

 Mastectomy

52

297

0.922

 BCS

5

30

 

Adjuvant chemotherapy

 Yes

18

148

0.048

 No

39

176

 

Adjuvant ET

 Yes

56

301

0.126

 No

1

23

 

Adjuvant RT

 Yes

39

235

0.524

 No

18

89

 

ypN stage

 0

40

95

<0.001

 1

11

109

 

 2

5

74

 

 3

1

48

 

LVI

 Yes

3

49

0.045

 No

54

278

 

Recurrence

 Yes

4

59

0.033

 No

51

250

 

Death

 Yes

4

30

0.567

 No

51

279

Â